Zollinger-Ellison syndrome: Recent advances and controversies

Current Opinion in Gastroenterology

Volumn 29, Issue 6, 2013, Pages 650-661

  Ito, Tetsuhide ^a   Igarashi, Hisato ^a   Jensen, Robert T ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Gastrin; gastrinoma; neuroendocrine tumor; pancreatic endocrine tumor syndrome; Zollinger Ellison syndrome

Indexed keywords

CAPECITABINE; DOXORUBICIN; ESOMEPRAZOLE; EVEROLIMUS; FLUOROURACIL; GASTRIN; INTERFERON; LANSOPRAZOLE; LUTETIUM 177; MICROSPHERE; OMEPRAZOLE; PANTOPRAZOLE; PROTEIN P53; RABEPRAZOLE; RETINOBLASTOMA PROTEIN; SECRETIN; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMOZOLOMIDE; YTTRIUM 90;

ARTIFICIAL EMBOLISM; ATROPHIC GASTRITIS; CANCER LOCALIZATION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROINTESTINAL CARCINOMA; HELICOBACTER INFECTION; HEPATOMEGALY; HUMAN; HYPERGASTRINEMIA; HYPERPARATHYROIDISM; INSULINOMA; KIDNEY FAILURE; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PATHOGENESIS; PATIENT CARE; PERNICIOUS ANEMIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH ACID SECRETION; STOMACH PH; SURVIVAL RATE; ZOLLINGER ELLISON SYNDROME;

DIAGNOSIS, DIFFERENTIAL; GASTRIC ACID; GASTRINOMA; HUMANS; PANCREATIC NEOPLASMS; ZOLLINGER-ELLISON SYNDROME;

EID: 84886091719     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328365efb1     Document Type: Review

References (153)

1. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment-advances. Best Pract Res Clin Gastroenterol 2012; 26:737-753.
2. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendo crine tumors. Langenbecks Arch Surg 2011; 396:299-311.
3. Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastro-enterol 2012; 26:819-831.
4. Leung D, Schwartz L. Imaging of neuroendocrine tumors. Semin Oncol 2013; 40:109-119.
5. Sundin A. Radiological and nuclear medicine imaging of gastroenteropan-creatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26:803-818.
6. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendo-crine tumors (pNETs): recent insights and advances. J Gastroenterol 2012; 47:941-960.
7. Kulke MH, Benson AB III, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012; 10:724-764.
8. Oberg K. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 2012; 24:433-440.
9. Ito T, Igarashi H, Uehara H, et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study-comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013; 92:135-181.
10. Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol 2013; 40:75-83.
11. de Herder WWE. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Best Pract Res Clin Gastroenterol 2012; 26:689-882.
12. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735-752.
13. Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95:98-119.
14. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84:173-182. (Pubitemid 46361051)
15. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469-1492.
16. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411.
17. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46:13-106.
18. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 1964; 160:512-530.
19. Ito T, Igarashi H, Uehara H, et al. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacotherapy 2013; 14:307-321.
20. Wilcox CM, Seay T, Arcury JT, et al. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis 2011; 43:439-443.
21. Lu YY, Zhu F, Jing DD, et al. Multiple endocrine neoplasia type 1 with upper gastrointestinal hemorrhage and perforation: a case report and review. World J Gastroenterol 2013; 19:1322-1326.
22. Sarkeshikian SS, Ghadir MR. A 41-year-old man with two types of meta-chronous peptic ulcer complication due to Zollinger-Ellison Syndrome-regression of pancreatic primary after chemoembolization of hepatic metastases: a case report. Case Report Med 2011; 2011:156937.
23. Thrumurthy SG, Date RS, Mughal MM, et al. The surgical management of pancreaticoduodenal tumours in multiple endocrine neoplasia type 1. BMJ Case Rep 2009 2009.
24. Simmons LH, Guimaraes AR, Zukerberg LR. Case records of the Massa-chusetts General Hospital. Case 6-2013. A 54-year-old man with recurrent diarrhea. N Engl J Med 2013; 368:757-765.
25. Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004; 83:43-83. (Pubitemid 38124855)
26. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med 1994; 97:436-444. (Pubitemid 24345595)
27. Jensen RT, Berna MJ, Bingham MD, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008; 113 (7 suppl):1807-1843.
28. Davi MV, Boninsegna L, Dalle Carbonare L, et al. Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. Neuroendocrinology 2011; 94:58-65.
29. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperaparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): longterm outcome of a more virulent form of HPT. Ann Surgery 2008; 247:501-510.
30. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243:477-488. (Pubitemid 28312244)
31. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315:1-5.
32. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999; 17:615-630. (Pubitemid 29075250)
33. Said R, O'Reilly EM, Blumgart L, et al. Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. Eur J Gastroenterol Hepatol 2010; 22:246-252.
34. Sreevathsa MR, Choudhury A. Long-term survival in a patient with carcinoid syndrome receiving treatment for Zollinger-Ellison syndrome. Int Surg 2009; 94:20-22.
35. Rustagi T, Siegel RD. Zollinger-ellison syndrome with subsequent association of insulinoma. JOP 2010; 11:486-488.
36. Morita Y, Suzuki S, Sakaguchi T, et al. Pancreatic neuroendocrine cell tumor secreting parathyroid hormone-related protein and gastrin: report of a case. Surg Today 2010; 40:1192-1196.
37. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142:709-728.
38. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duode-notomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004; 239:617-626. (Pubitemid 38525632)
39. Kloppel G, Anlauf M. Gastrinoma: morphological aspects. Wien Klin Wochenschr 2007; 119:579-584.
40. MacFarlane MP, Fraker DL, Alexander HR, et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-Type 1. Surgery 1995; 118:973-980.
41. Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7:114-121. (Pubitemid 40796696)
42. Thom AK, Norton JA, Axiotis CA, et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991; 110:1086-1093.
43. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228:228-238. (Pubitemid 30191719)
44. Evans JT, Nickles S, Hoffman BJ. Primary hepatic gastrinoma: an unusual case of Zollinger-Ellison syndrome. Gastroenterol Hepatol 2010; 6:53-56.
45. Lu X, Aoun E, Morrissey S. Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. BMJ Case Rep 2012 2012.
46. Naoe H, Iwasaki H, Kawasaki T, et al. Primary hepatic gastrinoma as an unusual manifestation of Zollinger-Ellison syndrome. Case Rep Gastroenterol 2012; 6:590-595.
47. Tarcin O, Yazici D, Ince U, et al. Bulky gastrinoma of the common bile duct: unusual localization of extrapancreatic gastrinoma: case report. Turk J Gastroenterol 2011; 22:219-223.
48. Ito T, Jensen RT. Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. Gastroenterol Hepatol (N Y) 2010; 6:57-59.
49. Jaenigen B, Kayser G, Steinke B, et al. Five-year long-term followup of a primary lymph node gastrinoma: is a pancreaticoduodenectomy justified? Case Rep Med 2009 2009; 762791:.
50. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637-1649.
51. Klimstra DS. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol 2013; 40:23-36.
52. Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18 (Suppl 1):S1-S16.
53. Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104:764-777.
54. Oberg K. The genetics of neuroendocrine tumors. Semin Oncol 2013; 40:37-44.
55. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331:1199-1203.
56. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21:1-14. (Pubitemid 46436730)
57. Hu W, Feng Z, Modica I, et al. Gene amplifications in well differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 2010; 1:360-368.
58. Tang LH, Contractor T, Clausen R, et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res 2012; 18:4612-4620.
59. Kloppel G, Anlauf M, Perren A. Endocrine precursor lesions of gastroenter-opancreatic neuroendocrine tumors. Endocr Pathol 2007; 18:150-155. (Pubitemid 351378066)
60. Vortmeyer AO, Huang S, Lubensky I, et al. Nonislet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89:1934-1938. (Pubitemid 38507955)
61. Anlauf M, Perren A, Henopp T, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut 2007; 56:637-644. (Pubitemid 46662928)
62. Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol 2012; 18:5495-5503.
63. Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2012; 10:126-130.
64. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012; 10:199-202.
65. Dhillo WS, Jayasena CN, Lewis CJ, et al. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem 2006; 43:153-155. (Pubitemid 43332337)
66. Murugesan SV, Varro A, Pritchard DM. Review article: strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009; 29:1055-1068.
67. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15:1555-1561. (Pubitemid 32912397)
68. Wong H, Yau T, Chan P, et al. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res 2010; 16:87-91.
69. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 2009; 11:433-441.
70. Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140:1444-1453.
71. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295-330. (Pubitemid 44772671)
72. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of longterm cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 119:199-206. (Pubitemid 23327619)
73. Shibata C, Kakyo M, Kinouchi M, et al. Criteria for the glucagon provocative test in the diagnosis of gastrinoma. Surg Today 2012.
74. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331-364. (Pubitemid 44772672)
75. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134:1842-1860. (Pubitemid 351783299)
76. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001; 80:189-222. (Pubitemid 32466460)
77. Goldman JA, Blanton WP, Hay DW, et al. Case report: false-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009; 7:600-602.
78. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroen-terol 2001; 96:3274-3280. (Pubitemid 34016648)
79. Stewart CA, Termanini B, Sutliff VE, et al. Management of Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 1997; 176:224-233.
80. Matok I, Gorodischer R, Koren G, et al. The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 2010; 50:81-87.
81. Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57:699-705.
82. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin b(12), iron, and magnesium. Curr Gastroenterol Rep 2010; 12:448-457.
83. Jensen RT. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98:4-19.
84. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenter-ology 2010; 139:1115-1127.
85. Termanini B, Gibril F, Sutliff VE III, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104:422-430. (Pubitemid 28274845)
86. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947-2953. (Pubitemid 46021498)
87. Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospective case-series and systematic review of the literature. Dig Liver Dis 2011; 43:380-385.
88. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123:68-85. (Pubitemid 34747527)
89. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cells changes in Multple endocrine neoplaisa type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93:1582-1591. (Pubitemid 351656492)
90. O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26:719-735.
91. Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99:943-950. (Pubitemid 20338449)
92. Klose KJ, Heverhagen JT. Localisation and staging of gastrin producing tumours using cross-sectional imaging modalities. Wien Klin Wochenschr 2007; 119:588-592. (Pubitemid 350060667)
93. Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med 1986; 105:841-847. (Pubitemid 17201757)
94. Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol 1984; 143:585-589. (Pubitemid 14067875)
95. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 1990; 174:25-29. (Pubitemid 20017077)
96. Frucht H, Norton JA, London JF, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroen-terology 1990; 99:1622-1627.
97. Morrow EH, Norton JA. Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am 2009; 89:1091-1103.
98. Frucht H, Doppman JL, Norton JA, et al. Gastrinomas: comparison of MR imaging with CT, angiography and US. Radiology 1989; 171:713-717.
99. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36:S106-S120. (Pubitemid 41115498)
100. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112:335-347. (Pubitemid 27078820)
101. Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882.
102. Naswa N, Sharma P, Soundararajan R, et al. Diagnostic performance of somatostatin receptor PET/CT using (68)Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 2013; 38:552-560.
103. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas-a prospective study. Ann Intern Med 1996; 125:26-34.
104. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773. (Pubitemid 39425767)
105. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341:635-644. (Pubitemid 29399042)
106. Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320-330. (Pubitemid 24313225)
107. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410-419.
108. Norton JA, Fraker DL, Alexander HR, et al. Value of surgery in patients with negative imaging and sporadic zollinger-ellison syndrome. Ann Surg 2012; 256:509-517.
109. Norton JA, Alexander HA, Fraker DL, et al. Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors-a prospective study. Ann Surg 2003; 237:650-659. (Pubitemid 38174531)
110. Nazir Z. Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. J Pediatr Surg 2011; 46: 969-972.
111. Anlauf M, Enosawa T, Henopp T, et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol 2008; 32:1101-1105.
112. Krampitz GW, Norton JA, Poultsides GA, et al. Lymph nodes and survival in duodenal and pancreatic neuroendocrine tumors. Arch Surg 2012; 47:820-827.
113. Bartsch DK, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg 2012; 99:1234-1240.
114. Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol 2012; 47:678-685.
115. Giovinazzo F, Butturini G, Monsellato D, et al. Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 2013; 65:19-24.
116. Fernandez-Cruz L, Blanco L, Cosa R, et al. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32:904-917.
117. Haugvik SP, Marangos IP, Rosok BI, et al. Long-term outcome of laparo-scopic surgery for pancreatic neuroendocrine tumors. World J Surg 2013; 37:582-590.
118. Atalar K, Warren OJ, Jacyna M, et al. Laparoscopic resection for primary lymph node gastrinoma. Pancreas 2013; 42:723-725.
119. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-506. (Pubitemid 32946712)
120. Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastro-enterol 2011; 17:1343-1353.
121. Lopez CL, Falconi M, Waldmann J, et al. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg 2013; 257:308-314.
122. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157-176.
123. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557-577.
124. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endo-crine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendo-crinology 2008; 87:47-62. (Pubitemid 350308294)
125. Harring TR, Nguyen NT, Goss JA, et al. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol 2011; 2011:1-11.
126. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2011; 18:3657-3665.
127. Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013; 216:123
128. Costa FP, Gumz B, Pasche B. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gas-troenterol 2012; 26:843-854.
129. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embo-lization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:131-144. (Pubitemid 46421904)
130. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemo-embolization and thermal ablation. Eur J Radiol 2009; 72:517-528.
131. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83:887-894.
132. Oberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 2012; 26:833-841.
133. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963-2970.
134. Pascher A, Klupp J, Neuhaus P. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19:637-648. (Pubitemid 41447723)
135. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroen-docrine tumors. N Engl J Med 2011; 364:514-523.
136. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513.
137. Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011; 364:564-565.
138. Bergsma H, van Vliet EI, Teunissen JJ, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012; 26:867-881.
139. Norton JA, Kirlen MA, Li M, et al. Morbidity and mortality of aggressive resections in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138:859-866. (Pubitemid 36960947)
140. Norton JA, Harris EJ, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 2011; 146:724-732.
141. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94:1326-1334.
142. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecita-bine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117:268-275.
143. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinomas. Cancer 2002; 94:331-343. (Pubitemid 34081361)
144. Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastro-enterology 1993; 105:1179-1183. (Pubitemid 23281509)
145. Blumberg J, Liyanage N, Caplin M. UK and Ireland NET Society/ENETs: The CLARINET study-Assessing the Effect of Lanreotide Autogel on Tumor Progression-Free Survival in patients with Non-Functioning Gastroentero- pancreatic Neuroendocrine Tumors (GEP-NETs) [abstract]. NANETs Symposium abstracts.2011 2012, Abstract #C4.
146. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
147. Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257:807-815.
148. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146:953-958.
149. Kulke MH, Bendell J, Kvols L, et al. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011; 4:29-37.
150. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine tumors version 1.2012. Version1.2012. 2012. online. go to www.nccn.org. Ref Type: Computer Program. in press.
151. van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neu-roendocrinology 2013; 97:74-85.
152. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124-2130.
153. Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377-1385.